Informações:
Falhas:
ID
13064
Descrição
D.T. PACE Versus High Dose Melphalan and Autologous Transplant in Patients With Previously Treated Multiple Myeloma; ODM derived from: https://clinicaltrials.gov/show/NCT00083876
Link
https://clinicaltrials.gov/show/NCT00083876
Palavras-chave
Versões (1)
- 14/01/2016 14/01/2016 -
Titular dos direitos
CC BY-NC 3.0
Transferido a
14 de janeiro de 2016
DOI
Para um pedido faça login.
Licença
Creative Commons BY-NC 3.0
Comentários do modelo :
Aqui pode comentar o modelo. Pode comentá-lo especificamente através dos balões de texto nos grupos de itens e itens.
Comentários do grupo de itens para :
Comentários do item para :
Para descarregar formulários, precisa de ter uma sessão iniciada. Por favor faça login ou registe-se gratuitamente.
Eligibility Multiple Myeloma NCT00083876
Eligibility Multiple Myeloma NCT00083876
- StudyEvent: Eligibility
Similar models
Eligibility Multiple Myeloma NCT00083876
- StudyEvent: Eligibility
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de dados
Alias
multiple myeloma
Item
patients must have previously treated (> 1 cycle prior therapy), active multiple myeloma requiring treatment. patients that have received >450 mg/m2 of prior adriamycin therapy are eligible, however, adriamycin will be deleted from the dt pace regimen in these patients.
boolean
C0026764 (UMLS CUI [1])
measurable disease
Item
patients must have measurable disease defined as one of the following: serum monoclonal protein >/= 1.0 mg/dl, or urine monoclonal protein >/= 1.0 grams/24 hour, or >/= 20% bone marrow plasmacytosis.
boolean
C2984963 (UMLS CUI [1])
C0085663 (UMLS CUI [2])
C0085663 (UMLS CUI [2])
eligibility
Item
all necessary baseline studies for determining eligibility must be obtained within 35 days prior to registration.
boolean
C0013893 (UMLS CUI [1])
performance status
Item
patients must have a performance status of 0-2 based on swog criteria.patients with a poor performance status (3-4), based solely on bone pain, will be eligible.
boolean
C1518965 (UMLS CUI [1])
platelet count
Item
patients must have a platelet count > or = 100,000/microliters. patients with platelet count < 100,000/microliters may be enrolled if it is felt to be due to extensive marrow plasmacytosis. the study coordinator must be consulted and dose modifications may apply.
boolean
C0005821 (UMLS CUI [1])
written informed consent
Item
all patients must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines.
boolean
C0021430 (UMLS CUI [1])
autotransplant or allograft
Item
patients must not have received a prior autotransplant or allograft.
boolean
C0472699 (UMLS CUI [1])
co-morbid medical conditions
Item
patients must not have significant co-morbid medical conditions or uncontrolled life threatening infection.
boolean
C0009488 (UMLS CUI [1])
cardiac disease
Item
patients with recent (< o= 6 months) myocardial infarction, unstable angina, difficult to control congestive heart failure, uncontrolled hypertension, or difficult to control cardiac arrythmias are ineligible. ejection fraction by echo or muga should be within the institutional normal range and must be performed within 42 days prior to registration.
boolean
C0018799 (UMLS CUI [1])
C0232174 (UMLS CUI [2])
C0232174 (UMLS CUI [2])
pulmonary diseases
Item
patients must not have a history of chronic obstructive or chronic restrictive pulmonary disease.patients must have adequate pulmonary function studies > or = 50% of predicted on mechanical aspects (fev1, fvc, etc) and diffusion capacity (dlco) > or = 50% of predicted. patients unable to complete pulmonary function tests due to myeloma related pain or fracture must have a high resolution ct scan of the chest and must also have acceptable arterial blood gases defined as p02 greater than 70.
boolean
C0024115 (UMLS CUI [1])
C0024119 (UMLS CUI [2])
C0024119 (UMLS CUI [2])
prior malignancy
Item
no prior malignancy is allowed except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancer for which the patient has been disease free for at least three years. prior malignancy is acceptable provided there has been no evidence of disease within the three-year interval and there must be no prior treatment with cytotoxic drugs that could potentially be assigned on this treatment protocol.
boolean
C0006826 (UMLS CUI [1])
pregnancy, contraception
Item
pregnant or nursing women may not participate. women of childbearing potential must have a negative pregnancy documented within one week of registration. women/men of reproductive potential may not participate unless they have agreed to use an effective contraceptive method.
boolean
C0032961 (UMLS CUI [1])
C0700589 (UMLS CUI [2])
C0700589 (UMLS CUI [2])